Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing novel products for the treatment of serious rare and ultra-rare genetic diseases. Founded in 2010 by Emil D. Kakkis, MD, PhD, the company pursues an array of drug modalities — including gene therapy, enzyme replacement therapy, and small molecules — selecting the best treatment strategy for each genetic disease in its pipeline. Ultragenyx has four approved therapies and one of the largest and most diverse rare disease pipelines, with over 20 programs across metabolic, bone, muscle, and neurologic diseases.